PT  - JOURNAL ARTICLE
AU  - Afzal, Abeer
AU  - Saif, Rashid
AU  - Atta, Asia
AU  - Jafri, Saghir Ahmad
AU  - Naqvi, Syeda Komal Abbas
TI  - Genetic Association of Glutathione S-Transferase Omega 2 <em>(GSTO2)</em> Gene Variant (rs156697) with Chronic Kidney Disease Patients of Pakistani Origin
AID  - 10.1101/2024.10.01.24313369
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.10.01.24313369
4099  - http://medrxiv.org/content/early/2024/10/01/2024.10.01.24313369.short
4100  - http://medrxiv.org/content/early/2024/10/01/2024.10.01.24313369.full
AB  - Chronic Kidney Disease (CKD) poses a significant global health challenge. The kidneys can be compromised by internal diseases, environmental influences and various genetic factors. Among the genetic factors, particularly, GSTO2 gene plays a crucial role in cellular processes and enzyme performance, which can lead to interstitial kidney damage and contribute to CKD. The current study investigates the genetic association between the GSTO2 gene variation (rs156697) and CKD in the Punjabi community. This study examined the association between the GSTO2 gene locus (c.424A>T) and CKD in a Punjabi population using ARMS-PCR genotyping. A total of 50 samples were analyzed, revealing 19 homozygous wild-type, 25 heterozygous and 6 homozygous mutants. PLINK data analysis toolset indicated an insignificant genotypic association with CKD phenotype with observed p-value of 0.7177 and an odds ratio of 0.85. Similarly, the alternative allele frequency of 0.34 and 0.375 was also observed in CKD and normal controls respectively. In the future, further studies with more genetic markers along with functional studies with large sample data may be performed for robust statistical evidence of the association of subject gene with CKD patients in Pakistan.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Institutional Review Board at NUR International University, in compliance with their Ethics Committee's regulations.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesN/A